Oxaliplatin in Treating Patients With Metastatic Bladder Cancer
Completed · Phase 2
Conditions studied: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating patients who have metastatic bladder cancer.
Key facts
- Study ID
- NCT00004203
- Run by
- University of Chicago
- People needed
- 20
- Starts
- 2000-02-01
- Expected to finish
- 2005-04-01
- Last updated by the study team
- 2013-09-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Illinois at Chicago — Chicago, Illinois, United States
- University of Chicago Cancer Research Center — Chicago, Illinois, United States
- Louis A. Weiss Memorial Hospital — Chicago, Illinois, United States
- Cancer Care Specialists of Central Illinois, S.C. — Decatur, Illinois, United States
- Evanston Northwestern Health Care — Evanston, Illinois, United States
- Division of Hematology/Oncology — Park Ridge, Illinois, United States
- Oncology/Hematology Associates of Central Illinois, P.C. — Peoria, Illinois, United States
- Central Illinois Hematology Oncology Center — Springfield, Illinois, United States
- Fort Wayne Medical Oncology and Hematology, Inc. — Fort Wayne, Indiana, United States
- Michiana Hematology/Oncology P.C. — South Bend, Indiana, United States
- University of Pennsylvania Cancer Center — Philadelphia, Pennsylvania, United States
- Cancer Care Ontario-Hamilton Regional Cancer Centre — Hamilton, Ontario, Canada
- Cancer Care Ontario-London Regional Cancer Centre — London, Ontario, Canada
- Princess Margaret Hospital — Toronto, Ontario, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.